Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- PXLW +19.4%, DATA +15.1%, FTNT +13%, PCTY +8.5%, BPY +7.7%, PFSI +5.6%, AVIR +5%, ESL +4.6%, IXYS +4.2%, V +3.9%, CY +3.6%, CLX +2.9%
- HMC +2.9%, CENT +2.7%, AMGN +2.5%, AIV +1.7%, ESS +1.6%, XPLR +1.2%, THG +1.2%
M&A news:
- CERU +13.9% (likely on continued M&A sepculation (strategic alternatives announced Feb 1))
Select financial names showing strength amid headlines that President Trump will begin acting today on plans to reduce regulatory burdens on the financial sector, with the review review Dodd-Frank and reversal of the Fiduciary Rule:
- BCS +2.5%, BAC +1.7%, GS +1.6%, C +1.4%, CS +0.7%, ING +0.7%
Other news:
- MDCO +10.5% (following Amgen's Repatha update and earnings)
- IPCI +10.4% (announces FDA acceptance for filing of NDA for Rexista (oxycodone hydrochloride extended release), an abuse deterrent opioid analgesic for the treatment of moderate to severe pain)
- ESPR +10% (following Amgen's Repatha update and earnings)
- SDRL +6.1% (modestly rebounding following recent weakness)
- AMGN +2.5% (announces Repatha significantly Reduced the risk of cardiovascular events in FOURIER Outcomes Study -- Landmark Repatha Cardiovascular Outcomes Study meets primary and key secondary endpoint)
- PANW +1.7% (in sympathy with FTNT earnings
- MA +1.3% (in sympathy with V earnings)
- REGN +1% (following Amgen's Repatha update and earnings)
Analyst comments:
- RIG +1.3% (upgraded to Outperform from Neutral at Credit Suisse )
- AMTD +1.3% (upgraded to Outperform from Neutral at Credit Suisse)
- F +0.9% (upgraded to Overweight from Equal Weight at Barclays )
- FCAU +0.7% (upgraded to Equal Weight at Barclays)